Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors

Core Insights - Tarsus Pharmaceuticals has appointed Dr. Katherine H. Goodrich, CMO of Humana Inc., to its Board of Directors, bringing over two decades of experience in innovative healthcare initiatives aimed at improving patient outcomes [1][2] Company Overview - Tarsus Pharmaceuticals focuses on unmet medical needs and aims to revolutionize treatment, particularly in eye care, by applying proven science and new technology [1][5] - The company is advancing its pipeline to address diseases with high unmet needs across various therapeutic categories, including eye care, dermatology, and infectious disease prevention [5] Leadership and Expertise - Dr. Goodrich has a significant background in value-based care, having previously served as CMO of Medicare and currently leading clinical initiatives at Humana [2][3] - Her role at Humana includes overseeing physician engagement, healthcare research, health equity, and social impact initiatives [2] - Dr. Goodrich has also held leadership positions at the Centers for Medicare and Medicaid Services, where she directed quality and value-based purchasing programs [3] Clinical Development - Tarsus is studying three investigational medicines in clinical trials, including XDEMVY, which is FDA approved for treating Demodex blepharitis, and two others targeting Meibomian Gland Disease and Rosacea, as well as an oral tablet for Lyme disease prevention [5]